Medicus Pharma closes $4.25M CEO-led equity raise, swaps $10.5M in debt
What's the deal? Medicus PharmaDealroom has a profile for this one. Try Dealroom → (NASDAQ: MDCX) has closed $4.25 million in fixed-price equity financings, led by chief executive officer and executive chairman Raza Bokhari through rbx capital lp. The Philadelphia biotech also exchanged $10.5 million of debt held by Streeterville CapitalDealroom has a profile for this one. Try Dealroom → for preferred shares.
The detail: A $1.25 million private placement — about 30% of the raise — came from insiders, including $750,000 from Bokhari. The remaining $3.0 million ran through a registered direct offering, with shares priced at $1.72. Maxim Group advised on that offering.
Why now? The transactions push Medicus's shareholders' equity above Nasdaq's $2.5 million continued-listing threshold. The company says that, subject to Nasdaq confirmation, it has regained compliance with listing rule 5550(b).
What's the endgame? Medicus is pivoting toward precision oncology, anchored by CD228V, an investigational antibody-drug conjugate licensed from Pfizer that targets melanotransferrin in melanoma and other solid tumours. The fresh cash funds working capital and development, management said, and insider participation signals "alignment with shareholders."
What could go wrong? The raise is modest against the company's finances. Medicus reported about $42.5 million in net equity and secured-debt proceeds over the first nine months of 2026, while liabilities climbed to $25 million from $10 million at the end of 2025. Its latest filing disclosed a shareholders' deficit and listing-compliance concerns.
The signal: The $10.5 million debt swap is not fresh funding — it reshapes existing obligations. Taken together, the moves read as another step in a sustained, mixed equity-and-debt effort to keep a small biotech listed and financed while it bets on a single clinical-stage cancer programme.
Read more: markets.financialcontent.com
Image credit: Generated with Gemini